IVVD
Invivyd
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About IVVD
Invivyd, Inc.
A biopharmaceutical company that develops antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and pre-emergent coronaviruses
1601 Trapelo Road, Suite 178, Waltham, MA 02451
--
Invivyd, Inc., was incorporated in Delaware on June 3, 2020. The company is a commercial-stage company with a mission to rapidly and permanently deliver antibody-based therapies to protect vulnerable populations from the devastating consequences of the pandemic virus threat, starting with SARS-CoV-2. The company's proprietary INVYMAB platform approach combines state-of-the-art virus surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid and continuous generation of new monoclonal antibodies (" MABs ") to keep pace with the evolving viral threat.
Company Financials
EPS
IVVD has released its 2024 Q4 earnings. EPS was reported at -0.15, versus the expected -0.10, missing expectations. The chart below visualizes how IVVD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IVVD has released its 2024 Q4 earnings report, with revenue of 13.82M, reflecting a YoY change of NaN%, and net profit of -18.44M, showing a YoY change of 74.96%. The Sankey diagram below clearly presents IVVD’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
